Objectives: To investigate possible cardiac morphofunctional alterations observed in 26 Turner’s syndrome (TS) patients on prolonged high-dose growth hormone (GH) therapy. Study Design: We examined 26 TS subjects treated with rhGH (1 U/kg/week) for a mean period of 4.9 years (range 1–7.8) and 37 age-, weight- and height-matched healthy girls. Left ventricular volume, mass, systolic function, cardiac index, systemic vascular resistance and diastolic function were evaluated by two-dimensional and Doppler echocardiography. Results: Heart rate and systolic blood pressure (BP) were higher in TS patients than in controls, while diastolic BP was lower. Left ventricular volumes, ejection fraction, mass index, M/V ratio and cardiac index did not differ significantly; systemic vascular resistance was slightly decreased. Left ventricular fractional shortening and mean velocity of circumferential shortening were slightly increased while end-systolic meridional stress was decreased in TS. Contractile state was normal in TS. Diastolic function assessment showed a shortening of isovolumetric relaxation and diastolic filling times with an increased atrial contribution and a normal pulmonary venous flow. Conclusion: Cardiac morphology in TS patients on GH therapy is similar to controls. The observed changes in left ventricular systolic and diastolic function should be interpreted as an adaptation to the higher heart rate and reduced peripheral vascular resistance induced by GH therapy.

Keywords:
Turner’s syndrome, Growth hormone, Heart, Echocardiography
1.
Rosenfeld RG, Attie KM, Frane J, Brasel JA, Burstein S, Cara JF, Chernausek S, Gotlin RW, Kuntze J, Lippe BM, Mahoney CP, Moore WV, Saenger P, Johanson AJ: Growth hormone therapy of Turner’s syndrome: Beneficial effect on adult height. J Pediatr 1998;132:319–324.
2.
Nilsson KO, Albertsson-Wikland K, Alm J, Aronson S, Gustafsson J, Hagenas L, Hager A, Ivarsson SA, Karlberg J, Kristrom B, Marcus C, Moell C, Ritzen M, Tuvemo T, Wattsgard C, Westgren U, Westphal O, Aman J: Improved final height in girls with Turner’s syndrome treated with growth hormone and oxandrolone. J Clin Endocrinol Metab 1996;81:635–640.
3.
Van den Broeck J, Massa GG, Attanasio A, Matranga A, Chaussain JL, Price DA, Aarskog D, Wit JM: Final height after long-term growth hormone treatment in Turner syndrome. J Pediatr 1995;127:729–735.
4.
Savage DD, Henry WL, Eastman RC, Borer JS, Gorden P: Echocardiographic assessment of cardiac anatomy and function in acromegalic patients. Am J Med 1979;67:823–829.
5.
Klein I, Ojamaa K: Cardiovascular manifestations of endocrine disease. J Clin Endocrinol Metab 1992;75:339–342.
6.
Radetti G, Crepaz R, Paganini C, Gentili L, Pitscheider W: Medium-term cardiovascular effects of high-dose growth hormone treatment in growth hormone deficient children. Horm Res 1999;52:247–252.
7.
Saenger P, Wesoly S, Glickstein J, Appel P, Issenberg H: No evidence for ventricular hypertrophy in Turner’s syndrome after growth hormone therapy; in Turner’s Syndrome in a Life-Span Perspective. Amsterdam, Elsevier Science, 1995, pp 259–262.
8.
De Schepper J, Craen M, Massa G, Heinrichs C, Maes M, Du Caju M, Rausin L, Bourguignon JP: Growth hormone therapy in Turner’s syndrome: One versus two daily injections. J Clin Endocrinol Metab 1994;79:489–494.
9.
Sas TC, Cromme-Dÿkhuis AH, de Muinck Keizer-Schrama SM, Stÿnen T, van Teunenbroek A, Drop SL: The effects of long-term growth hormone treatment on cardiac left ventricular dimensions and blood pressure in girls with Turner’s syndrome. Dutch Working Group on Growth Hormone. J Pediatr 1999;135:470–476.
10.
Greulich WW, Pyle SL: Radiographic Atlas of Skeletal Development of the Hand and Wrist, ed 2. Stanford, Stanford University Press, 1969.
11.
Tanner JM, Whitehouse RH, Takaishi M: Standards from birth to maturity for height, weight, height velocity and weight velocity: British children. Arch Dis Child 1966;41:613–635.
12.
Rolland-Cachera MF, Cole TJ, Sempé M, Tichet J, Rossignol C, Charraud A: Body mass index variations: Centile from birth to 87 years. Eur J Clin Nutr 1991;45:13–21.
13.
Vuille C, Weyman A: Left ventricle: General consideration, assessment of chamber size and function. in Weyman AE (ed): Principle and Practice of Echocardiography. Philadelphia, Lea & Febiger, 1994, p 575.
14.
Sanders SP: Echocardiography; in Long WA (ed): Fetal and Neonatal Cardiology. Philadelphia, Saunders, 1990, p 301.
15.
Teichholz LE, Kreulen T, Herman MV, Gorlin R: Problems in echocardiographic volume determinations: Echocardiographic-angiographic correlations in the presence or absence of asynergy. Am J Cardiol 1976;37:7–11.
16.
Devereux RB, Alonso DR, Lutas-Gottlieb GJ, Campo E, Sachs I, Reichek N: Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findings. Am J Cardiol 1986;57:450–458.
17.
Franklin RCG, Wyse RKH, Graham TP, Gooch VM, Deanfield JE: Normal values for noninvasive estimation of left ventricular contractile state and afterload in children. Am J Cardiol 1990;65:505–510.
18.
Crepaz R, Pitscheider W, Radetti G, Gentili L: Age-related variation in left ventricular myocardial contractile state expressed by the stress velocity relation. Pediatr Cardiol 1998;19:463–467.
19.
Grossmann W, Jones D, McLaurin LP: Wall stress and pattern of hypertrophy in the human left ventricle. J Clin Invest 1975;56:56–62.
20.
Borow KM, Neumann A, Wynne J: Sensitivity of end-systolic pressure-dimension and pressure-volume relations to the inotropic state in humans. Circulation 1982;65:988–996.
21.
Yawahara M, Benson LN, Freedom RM: Noninvasive estimation of end-systolic aortic pressure in children. Echocardiography 1991;8:559–562.
22.
Colan S: Noninvasive assessment of myocardial mechanics – A review of analysis of stress shortening and stress velocity. Cardiol Young 1992;2:1–13.
23.
Snider AR, Gidding SS, Rocchini AP, Rosenthal A, Dick MD, Crowley DC, Peters J: Doppler evaluation of left ventricular diastolic filling in children with systemic hypertension. Am J Cardiol 1985;56:921–926.
24.
Bowmann LK, Lee FA, Jaffe CC, Mattera J, Wackers FJ, Zaret BL: Peak filling rate normalized to mitral stoke volume: A new Doppler echocardiographic filling index validated by radionuclide angiographic techniques. J Am Coll Cardiol 1988;12:937–943.
25.
O’Leary PW, Durongpisitkul K, Cordes, TM Bailey KR, Hagler DJ, Tajik J, Seward JB: Diastolic ventricular function in children: A Doppler echocardiographic study establishing normal values and predictors of increased ventricular end diastolic pressure. Mayo Clin Proc 1998;73:616–628.
26.
Saccà L, Cittadini A, Fazio S: Growth hormone and the heart. Endocr Rev 1994;15:555–573.
27.
Mathews LS, Enberg B, Norsted G: Regulation of rat growth hormone receptor gene expression. J Biol Chem 1989;264:9905–9910.
28.
Turner JD, Rotwein P, Novakofski J, Bechtel PJ: Induction of mRNA for IGF-I and -II during growth hormone-stimulated muscle hypertrophy. Am J Physiol 1988;255:E513–E517.
29.
Ito H, Hiroe M, Hirata Y, Tsujino M, Adachi S, Shichiri M, Koike A, Nogami A, Marumo F: Insulin-like growth factor-I induces hypertrophy with enhanced expression of muscle-specific genes in cultured rat cardiomyocytes. Circulation 1993;87:1715–1721.
30.
Thuesen L, Christiansen JS, Sørensen KE, Jørgensen JOL, Ørskov H, Henningsen P: Increased myocardial contractility following growth hormone administration in normal man. Dan Med Bull 1988;35:193–196.
31.
Caidahl K, Edén S, Bengtsson BÅ: Cardiovascular and renal effects of growth hormone. Clin Endocrinol (Oxf) 1994;40:393–400.
32.
Reaven GM, Lithell H, Landsberg L: Hypertension and associated metabolic abnormalities – The role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996;334:374–381.
33.
Copeland KC, Nair KS: Recombinant human insulin-like growth factor-I increases forearm blood flow. J Clin Endocrinol Metab 1994;79:230–232.
34.
Elsheikh M, Conway GS: The impact of obesity on cardiovascular risk factors in Turner’s syndrome. Clin Endocrinol (Oxf) 1998;49:447–450.
35.
Lin AE, Lippe B, Rosenfeld RG: Further delineation of aortic dilation, dissection and rupture in patients with Turner syndrome. Pediatrics 1998;102:12.
36.
Hochberg Z, Aviram M, Rubin D, Pollack S: Decreased sensitivity to insulin-like growth factor I in Turner’s syndrome: A study of monocytes and T lymphocytes. Eur J Clin Invest 1997;27:543–547.
37.
Zadik Z, Landau H, Chen M, Altman Y, Lieberman E: Assessment of growth hormone (GH) axis in Turner’s syndrome using 24-hour integrated concentrations of GH, insulin-like growth factor-I, plasma GH-binding activity, GH binding to IM9 cells, and GH response to pharmacological stimulation. J Clin Endocrinol Metab 1992;75:412–416.
© 2001 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.